Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-labeled HER2-targeted Antibody Fragments PET Imaging
NCT07023848Phase 1Enrolling by invitation
- Sponsor
- Affiliated Hospital of Jiangnan University
- Start
- Jul 2025
- Primary completion
- Jul 2026
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of 89Zr-LNCab103 and 89Zr-LNCab104 in breast cancer, gastric cancer (GC) and urothelial carcinoma (UC) (3 arms), sponsored by Affiliated Hospital of Jiangnan University. Primary endpoints: Tumor Uptake Value (SUVmax) of HER2-Targeted PET/CT Compared with 18F-FDG PET/CT and Number of Lesions Detected by HER2-Targeted PET/CT Compared with 18F-FDG PET/CT. Started Jul 2025; status: enrolling by invitation.
02
Drugs
89Zr-LNCab10389Zr-LNCab104
03
Conditions
breast cancergastric cancer (GC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07023848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07023848.